Is pregabalin a controlled substance
Pro Research Analysisby 
Searched over 200M research papers
Pregabalin as a Controlled Substance
Introduction to Pregabalin
Pregabalin is a medication primarily used to treat neuropathic pain, fibromyalgia, and as an adjunctive therapy for partial-onset seizures. It is known for its efficacy in managing conditions such as diabetic peripheral neuropathy and postherpetic neuralgia . However, due to its potential for misuse and abuse, various regulatory bodies have reclassified pregabalin as a controlled substance.
Reclassification in the UK
In the UK, pregabalin has been reclassified as a class C controlled substance. This decision was driven by a significant increase in deaths associated with its misuse. The reclassification aims to curb the growing misuse and addiction problems linked to pregabalin 127. The British Medical Association (BMA) has also advocated for this reclassification to address the widespread issues of misuse and addiction .
Regulatory Changes and Impact
The reclassification of pregabalin in the UK, effective from April 2019, has introduced stricter controls on its prescribing, dispensing, and collection. These changes are expected to reduce the drug's misuse by making it more challenging to obtain . Similar measures have been implemented in Saudi Arabia, where the Saudi Food and Drug Authority added pregabalin to the list of controlled substances in December 2017 to minimize its abuse and misuse .
Classification in the United States
In the United States, pregabalin is classified as a Schedule V controlled substance under the Controlled Substances Act. This classification subjects pregabalin to regulatory controls and criminal sanctions related to its manufacture, distribution, dispensing, importation, and exportation . The classification reflects the drug's potential for abuse and dependence, although it is considered to have a lower potential for abuse compared to drugs in Schedules I-IV .
Conclusion
Pregabalin's reclassification as a controlled substance in various countries underscores the growing concerns about its misuse and associated risks. These regulatory changes aim to mitigate the potential for abuse while ensuring that patients who genuinely need the medication can still access it under stricter controls. The global trend towards tighter regulation highlights the importance of balancing the therapeutic benefits of pregabalin with the need to prevent its misuse and protect public health.
Sources and full results
Most relevant research papers on this topic
The impact of regulatory restrictions on pregabalin use in Saudi Arabia: An interrupted time series analysis
The addition of pregabalin to the controlled substances list in Saudi Arabia has significantly reduced its use compared to other drugs for treating neuropathic pain.
Subjective, Psychomotor, and Physiological Effects of Pregabalin Alone and in Combination With Oxycodone in Healthy Volunteers
Pregabalin may increase subjective effects and decrease respiration rate when combined with oxycodone, but does not increase drug liking or desire to take the drug again.
Pregabalin: an antiepileptic agent useful for neuropathic pain.
Pregabalin may be beneficial for treating neuropathic pain or partial-onset seizures in patients who do not respond to conventional treatments or cannot tolerate their adverse effects.
DOI